Navigation Links
Combination therapy shows promising results in patients with advanced lung cancer

advanced lung cancer.

The study was part of the Specialized Program of Research Excellence (SPORE) in lung cancer at UCLA's Jonsson Cancer, a program funded by the National Cancer Institute at top research institutions nationwide to find better and more effective ways to prevent, detect and treat lung cancer.

"This trial is an important early step in utilizing combination targeted therapies in lung cancer," said Dr. Steven Dubinett, director of UCLA's lung cancer SPORE and a professor of pulmonary and critical care medicine. "Dr. Reckamp's trial is the first to study increasing doses of a COX-2 inhibitor in lung cancer in an attempt to define an optimal biological dose. Larger trials of combination therapies utilizing this dose will now be required."

The biology of an individual's tumor determines whether they will respond to Tarceva. Because researchers don't yet fully understand what biologic characteristics determine response, they can't test patients first to determine who should be given the drug. Since 90 percent of patients don't respond to Tarceva, the drug was not an option for them. Reckamp said a portion of those may now be able to take Tarceva combined with Celebrex.

Because they target what is broken in a cancer cell and leave the healthy cells alone, therapies like Tarceva cause fewer side effects than conventional therapies such as chemotherapy, which targets all fast growing cells and often results in debilitating side effects. Reckamp characterized the side effects seen with the combination therapy as minor.

The next step is a larger Phase II study to confirm the efficacy of the combination therapy and further probe the mechanisms of Tarceva resistance, Reckamp said. That study is expected to begin at UCLA in the fall.

Reckamp's study was the first to determine the safest and most effective dose of Celebrex to use in lung cancer. Previously, doses were based on studies done in colon cancer patients.'"/>

Source:University of California - Los Angeles


Page: 1 2 3

Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. Combination therapy leads to partial recovery from spinal cord injury in rats
3. Combination therapy improves AIDS-related lymphoma outcome
4. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity

Post Your Comments:
(Date:11/30/2009)...v. 30, 2009) Scientists and engineers from two of...rgy will come together Dec. 7 with leading academ...pumping blood. , Much like moving oil through a ...dy. Both systems need clean, well-functioning pip...ion, to function efficiently. Both industries also...
(Date:11/30/2009)...age of lower early bird registration rates and reg...gress of 2010 at http://www.iofwco-ecceo10.org/ ...the International Osteoporosis Foundation (IOF) an...spects of Osteoporosis and Osteoarthritis (ESCEO)....d are expected to attend. The exciting scientific ...
(Date:11/30/2009)...a colorless and odorless radioactive gas that is p... is a product of uranium decay and is found in tra...nd groundwater as well as building materials, plan...tration is expressed as the amount of radiation th...s in a liter of air; thus the units are picocuries...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3Health Physics Society recommends considering action for indoor radon below current guidelines 2Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 50684 1Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 50684 2Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 50684 3Kids With Type 1 Diabetes Often Overweight 50682 1Kids With Type 1 Diabetes Often Overweight 50682 2JNCI news brief 3A Hepatitis B virus mutations may predict risk of liver cancer 50680 1
...Wake Forest University School of Medicine have suc...anded them in the laboratory and coaxed them into ...e of the first studies to show the ability of a si...es, is reported today in Stem Cells and Developmen...ce for tissue repair and for organs as well," said...
...ng the genomes of both humans and chimpanzees has ...the two species came about in events called segmen...e are copied many times in the genome. The study a...e of the chimpanzee genome published in the Sept. ... associate professor of genome sciences at the Uni...
Camera Traps Reveal Rare Asiatic Cheetahs
Other Biology News:Researchers grow stem cells from human skin 2Big differences in duplicated DNA distinguish chimp and human genomes 2
(Date:11/30/2009)... , BLOOMINGTON, Minn., Nov. 30 ... medical image management software, data migration...ith Allina Hospitals and Clinics for a new Vendor ... image storage across the Allina network of hospit...olution is based on the Acuo Technologies DICOM Se...
(Date:11/30/2009)... , AMSTERDAM, November 30 ... today that the first patients have been enrolled ...ith ATIR(TM). The study is,designed to show reduct...e,year following an allogeneic stem cell transplan...n blood cancer patients eligible for an allogeneic...
(Date:11/30/2009)... , NOVATO, Calif., Nov. 30 /PRNewswire-FirstCal...) announced today that the Food and Drug Administr...r 3,4-diaminopyridine (3,4-DAP), amifampridine pho...ton Myasthenic Syndrome (LEMS). 3,4-DAP has previ... Also, in October 2009, the Committee for Medicin...
(Date:11/30/2009)... , SHANGHAI, Nov. 30 /PRNewswire-Asia...maceutical, biotechnology, and medical-device rese...ations in China and the United States,announced t...y Fast 50 China,2009 list for the fifth consecutiv... companies in China,s technology, media, and telec...
Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2
...mments as much as a poor customer experience. No ...awn as much comment as the one I wrote in early F... update: My Cingular saga has only gotten worse. I...ustomer. I was traveling intensively and unexpecte... my first month,s payment was past due by about 10...
...nt Technologies Corp. (NYSE:SXT) reported $12.8 m...r its first quarter ended March 31. Diluted earnin...anufacturer and marketer of colors, flavors and fr... same quarter last year. Total debt was $596 milli...he first quarter include a one-time expense of $4....
...a day of interesting juxtapositions. , ,I spent th...005, where one of the hot topics was the shift fro...ng was that it,s easier to grow per-employee reven... that its year over year earnings were doing a fai...a slower than expected shift in the revenue stream...
Other Biology Technology:Readers react to 'Cingular confusion' 2Readers react to 'Cingular confusion' 3Readers react to 'Cingular confusion' 4IBM takes one direction, Milwaukee entrepreneurs the other 2IBM takes one direction, Milwaukee entrepreneurs the other 3
...NA Polymerase I Large (Klenow) Fragment, Exonuclea...acks both the 5´→3´ and the 3´...intact E. coli DNA Polymerase I (1,2). It is used ...placement amplification (5). Klenow Fragment, Exon...
Goat Anti-Human SMVT (N-14) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Combiplate 8 from Thermo Scientific
...abbit polyclonal to Dideoxycytidine Dideoxycytidi...effective in inhibiting retroviral activity. Imm...SA. Specificity: The specificity of the ddC ant...the moles of ddC to moles of ddC analog at the 50%...
Biology Products: